Home/ Stocks/ ACHV

Achieve Life Sciences, Inc.

ACHV XNAS

$5.21 +0.43 (+8.98%) ▲ 15-min delayed

Open

$4.81

High

$5.35

Low

$4.74

Volume

1.76M

Market Cap

$534.85M

About Achieve Life Sciences, Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Sector: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES Employees: 28 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	N/A	$-54,648,000	$-1.25
FY 2025	N/A	$-54,648,000	$-1.25
Q3 2025	N/A	$-14,441,000	$-0.28
Q2 2025	N/A	$-12,718,000	$-0.37

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for ACHV yet. Check out our latest market news or earnings calendar.

Get ACHV Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Achieve Life Sciences, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.